Tectonic Therapeutic, Inc. TECX
Tectonic Therapeutic, Inc. (Nasdaq: TECX) is a cardio-renal-metabolic drug developer. Its lead program, TX45, is in Phase 2 for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). Its next catalyst on record is TX2100 TERRA: Initiation of Phase 1b trial in HHT patients (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TX2100 TERRA — Initiation of Phase 1b trial in HHT patients (2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TX45 | PH-HFpEF | protein/peptide | Phase 2 |
| TX45 | PH associated with Interstitial Lung Disease (PH-ILD) | protein/peptide | Phase 2 |
| TX2100 | Hereditary Hemorrhagic Telangiectasia (HHT) | antibody | Phase 1 |
Recent results and decisions
- Oct 31, 2026started First patient dosed in the ALPINE Phase 2a clinical trial of TX45 in PH-ILD in October 2026.
In October 2026, Tectonic dosed the first PH-ILD patient in the TX45 ALPINE Phase 2a clinical trial.
Filing - Sep 30, 2026positive TX2100 Phase 1a single ascending-dose trial reported favorable safety, tolerability and PK results in healthy adult volunteers.
There were no serious adverse events or severe treatment-emergent adverse events at any dose, and no clinically significant or dose-related changes were observed in vital signs including blood pressure, or laboratory assessments.
Filing - Sep 30, 2026n/a FDA granted TX2100 Fast Track designation for Hereditary Hemorrhagic Telangiectasia in September 2026.
FDA granted TX2100 Fast Track designation for HHT in September 2026 and cleared the Investigational New Drug application in August 2026 for the planned Phase 1b clinical trial.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.